Despite the headwinds facing the industry, a growing number of leading pharmaceutical companies feature on Thomson Reuters’ annual Top 100 Global Innovators list, as Bob Stembridge reports.
Life sciences companies do not do research and development (R&D) like everyone else. With longer innovation cycles, several well-defined layers of regulatory approval and various global hurdles to overcome, patent volumes in the pharmaceutical industry are often dwarfed by those of fast-moving industries such as semiconductors and consumer electronics, which tend to steal the spotlight when it comes to showcasing innovation.
Does that make pharma companies any less innovative? No. In fact, despite the obvious headwinds facing the industry, a growing number of leading pharmaceutical companies have been showing up on Thomson Reuters’ annual Top 100 Global Innovators list.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
Thomson Reuters’ annual Top 100 Global Innovators list; patents; innovation; pharmaceutical